Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Shingles vaccine study aims to protect transplant patients

NCT ID NCT06262776

First seen Apr 29, 2026 · Last updated May 23, 2026 · Updated 4 times

Summary

This study looks at how transplant patients, who take different medicines to suppress their immune system, respond to the shingles vaccine compared to their healthy housemates. About 160 people will get two doses of the SHINGRIX vaccine, and their immune responses will be checked over a year. The goal is to understand if the vaccine works well for people with weakened immune systems.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IMMUNOSUPPRESSION are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Royal Adelaide Hospital

    RECRUITING

    Adelaide, South Australia, 5000, Australia

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.